Clinical trials: Epithelial Neoplasms, Malignant
Basal Cell Carcinoma
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome.
- Trial name
- NCT01604252
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 503 people
- Sponsor
- Genentech, Inc.
Thyroid Cancer
Myeloid Cell Reprogramming in Thyroid Carcinoma
This study investigates the reprogramming of myeloid cells in patients with thyroid carcinoma. The investigators hypothesize that tumor-derived factors change the function of myeloid cells (peripheral blood and bone…
- Trial name
- NCT03397238
- Where
- Netherlands
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
NSCLC
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will receive only chemotherapy.
- Trial name
- NCT02766348
- Testing
- gemcitabine, DC-CTL, cisplatinum
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Hepatocellular Carcinoma
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
This study will examine the effects of a six-month regimen of neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma…
- Trial name
- NCT05171335
- Testing
- Lenvatinib, Transcatheter Arterial Chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer, Metastatic Castration-resistant Prostate Carcinoma
Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity
Docetaxel is used as a first line anti-cancer drug in the treatment of several cancers, mainly breast- and metastatic castration-resistant prostate carcinoma.
- Trial name
- LEANDOC (NCT01621425)
- Testing
- Lean body mass, Total body weight, bloodsampling
- Where
- 2 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Radboud University Medical Center
Carcinoma, Non-small-cell Lung Cancer
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02696525
- Where
- 3 sites in China
- Volunteers
- 145 people
- Sponsor
- Peking University People's Hospital
Glioblastoma, Glioblastoma Multiforme
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM
- Trial name
- NCT05271240
- Testing
- Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation, Temozolomide and Radiation Alone
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Northwell Health
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the…
- Conditions
- Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Trial name
- THREAD (NCT03825289)
- Testing
- Hydroxychloroquine, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Renal Cancer Metastatic
Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
NIVES study is an ongoing phase II, single arm, multicenter study. In this trial pts received SBRT to one non-brain measurable lesion and concomitant NIVOLUMAB, an anti-programmed cell death (PD-1).
- Trial name
- NIVES (NCT03469713)
- Testing
- Nivolumab
- Where
- Italy
- Volunteers
- 69 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Solid Tumor
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.
- Trial name
- NCT05798533
- Testing
- Neo-T, Toripalimab, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- BGI, China
Non-small Cell Lung Cancer
Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial
Concurrent chemoradiotherapy is the standard treatment for locally advanced, unresectable non-small cell lung cancer, but carries a risk of radiation pneumonitis of approximately 30%, and is associated with a decline in pulmonary…
- Trial name
- FLAIR (NCT02002052)
- Testing
- Concurrent platinum-based chemotherapy, Standard Radiotherapy, 60 Gy in 30 fractions., Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
MET Positive, Recurrent Squamous Cell Lung Carcinoma
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
This randomized phase II/III compares rilotumumab when given together with erlotinib hydrochloride against erlotinib hydrochloride alone in treating patients with stage IV squamous cell lung cancer that has come back after…
- Conditions
- MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02926638
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Rilotumumab
- Where
- 627 sites in United States
- Volunteers
- 9 people
- Sponsor
- SWOG Cancer Research Network
Atypical Ductal Hyperplasia, Ductal Carcinoma in Situ
Excisional Vacuum-Assisted Breast Biopsy
The goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (VAE) to completely remove the pathology in case of small lesions for Atypical Ductal Hyperplasia (ADH) and…
- Trial name
- NCT05932758
- Testing
- Vacuum-assisted excisional biopsy, Not excisional biopsy
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- European Institute of Oncology
HCC, Portal Vein Tumor Thrombosis
ISP-TACE Versus TACE for HCC With PVTT
For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest.
- Trial name
- NCT03108248
- Testing
- ethiodized oil; doxorubicin;Gelfoam;, stent; idoine-125
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular
Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment
An open label, single arm, Phase II study of avelumab in patients with advanced hepatocellular carcinoma after prior sorafenib treatment
- Trial name
- AvelumabHCC (NCT03389126)
- Testing
- Avelumab
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Urothelial Carcinoma of the Renal Pelvis and Ureter, Transitional Cell Cancer of the Renal Pelvis and Ureter
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
The goal of this prospective clinical trial is to investigate the safety and efficacy of ST-02 (mucoadhesive gemcitabine suspension for pyelocaliceal instillation) to treat Upper Tract Urothelial Carcinoma (UTUC) in participants…
- Trial name
- NCT06124976
- Testing
- ST-02
- Where
- 8 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Peter Black
Pancreatic Cancer
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating…
- Trial name
- NCT01088789
- Testing
- Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astrocytoma, Grade IV, Glioblastoma
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
The main purposes of this study are: I. To assess that the four habitats within the tumor (HAT and LAT) and edema (IPE and VPE) in high-grade glioma are different at vascular, tissular, cellular and molecular levels. II.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype
- Trial name
- BIOhabitats (NCT05375318)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Juan M Garcia-Gomez
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent).
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
- Trial name
- NCT04183218
- Testing
- Biospecimen Collection, Cardiac Event Monitor, Chemoradiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.